Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: A randomized, double-blind, placebo-controlled trial

International Journal of COPD

Volumn 9, Issue , 2014, Pages 179-186

  Siva, Roshan ^a   Bafadhel, Mona ^b   Monteiro, William ^c   Brightling, Christopher E ^c   Pavord, Ian D ^b  

^a MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Antibiotics; Bacteria; Sputum

Indexed keywords

LEVOFLOXACIN; PLACEBO;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL LOAD; BACTERIUM EXAMINATION; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEUTROPHIL COUNT; NEUTROPHILIC AIRWAY INFLAMMATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SPUTUM ANALYSIS; TREATMENT RESPONSE;

ANTIBIOTICS; BACTERIA; SPUTUM;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTERIAL LOAD; DOUBLE-BLIND METHOD; ENGLAND; FEMALE; HUMANS; LEVOFLOXACIN; LUNG; MALE; MIDDLE AGED; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894745981     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S55419     Document Type: Article

References (31)

1. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555.
2. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645-1648.
3. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128(4):1995-2004.
4. Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003; 167(8):1090-1095.
5. O'Donnell RA, Peebles C, Ward JA, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax. 2004;59(10):837-842.
6. Kanazawa H, Hirata K, Yoshikawa J. Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients. Chest. 2003;123(2): 596-599.
7. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax. 1996;51(3):267-271.
8. Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med. 2002;166(1): 105-110.
9. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653.
10. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J. 2004;23(5):685-691.
11. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6): 662-671.
12. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57(9):759-764.
13. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114-1121.
14. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax. 2003;58(8):680-685.
15. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000;109(4): 288-295.
16. Marin A, Monsó E, Garcia-Nuñez M, et al. Variability and effects of bronchial colonisation in patients with moderate COPD. Eur Respir J. 2010;35(2):295-302.
17. Pavord ID, Sterk PJ, Hargreave FE, et al. Clinical applications of assessment of airway inflammation using induced sputum. Eur Respir J Suppl. 2002;37:40s-43s.
18. Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996; 154(2 Pt 1):308-317.
19. Brightling CE, Monterio W, Green RH, et al. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. Respir Med. 2001;95(12):999-1002.
20. Health Protection Agency. Investigation of bronchoalveolar lavage, sputum and associated specimens. National Standard Method BSOP 57 Issue 2.3 Available from: http//www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317132860548. Accessed on November 12, 2013.
21. Pye A, Stockley RA, Hill SL. Simple method for quantifying viable bacterial numbers in sputum. J Clin Pathol. 1995;48(8):719-724.
22. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638-1645.
23. Stockley RA, Hill AT, Hill SL, Campbell EJ. Bronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiency. Chest. 2000;117(5 Suppl 1):291S-293S.
24. Stockley RA, Hill SL, Morrison HM. Effect of antibiotic treatment on sputum elastase in bronchiectatic outpatients in a stable clinical state. Thorax. 1984;39(6):414-419.
25. Sethi S, Jones PW, Theron MS, et al; PULSE Study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10.
26. Albert RK, Connett J, Bailey WC, et al; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698.
27. Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother. 2002;49(5):709-712.
28. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med. 1997;156(1):266-271.
29. Kadir T, Izzetin FV, Cevikba̧ A, Johansson CB, Clark P. In vitro effects of clarithromycin on human polymorphonuclear leukocyte functions. Chemotherapy. 2000;46(3):198-203.
30. Wilson R, Allegra L, Huchon G, et al; MOSAIC Study Group. Short term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125(3):953-964.
31. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD:MAESTRAL results. Eur Respir J. 2012;40(1):17-27.